Private-Label Pharmaceutical Feasibility Study

1 Executive Summary

This feasibility study evaluates the commercial, regulatory, and operational viability of launching a private-label pharmaceutical division within Aevum Zenth Health Sciences. The proposed entity will focus on generic APIs, OTC formulations, and specialty contract manufacturing for institutional buyers.

After comprehensive analysis of market demand, regulatory pathways, supply chain infrastructure, and financial modeling, the study concludes that the initiative is highly viable with a projected break-even at Month 18 and an IRR of 24.6% over a 5-year horizon. Strategic alignment with existing Zenth logistics, R&D, and compliance frameworks significantly reduces time-to-market and operational overhead.

2 Market Opportunity & Demand Analysis

The global private-label pharmaceutical market is experiencing structural growth driven by healthcare cost containment, retail pharmacy expansion, and institutional procurement shifts. Aevum Zenth's integrated distribution network and existing B2B relationships position the division to capture significant market share within 36 months.

Key Market Drivers

• Healthcare Cost Optimization: Payers and retail chains increasingly favor private-label generics (30-50% cost reduction vs branded)
• Retail Pharmacy Expansion: Private-label OTC and wellness categories growing at 18% CAGR across North America and EMEA
• Institutional Procurement: Hospitals and government health systems prefer standardized, audited private-label APIs for volume purchasing

3 Regulatory & Compliance Pathway

Regulatory compliance represents the highest initial barrier but aligns with Zenth's existing quality management infrastructure. The division will operate under FDA 21 CFR Part 210/211, EMA GMP, and ISO 13485 standards.

Compliance Framework

1. Facility Certification: Phase 1 requires FDA Establishment Registration & Drug Listing (FERDL) and EU GMP certification (estimated 6-8 months)
2. Quality Management System: Implementation of QMS v4.0 integrated with Zenth's centralized audit platform
3. Pharmacovigilance: Dedicated PV unit reporting to FDA/EMA adverse event databases with automated signal detection
4. Supply Chain Traceability: DSCSA-compliant serialization and track-and-trace infrastructure from API to finished dosage

Estimated Compliance Budget: $14.2M (Year 1), transitioning to $3.8M annual maintenance thereafter. Leverages existing Zenth Legal & Regulatory Affairs division to reduce external consultancy costs by ~35%.

4 Manufacturing & Quality Assurance

Initial operations will utilize a hybrid model: core formulation and packaging in-house, with strategic API synthesis outsourced to vetted CDMOs. This approach optimizes CAPEX while maintaining quality control.

Facility & Capacity Planning

• Primary Site: 120,000 sq. ft. GMP-compliant facility (Knoxville, TN or Midlands, UK)
• Throughput: 4.2M units/month (tablets/capsules), scalable to 8.5M via modular line expansion
• Quality Control: In-house HPLC, GC-MS, dissolution testing, and stability chambers
• Automation: AI-driven batch record generation and real-time release testing (RTRT) integration

Cross-utilization of Aevum Logistics' cold-chain and temperature-controlled distribution network reduces last-mile fulfillment costs by an estimated 22%.

5 Financial Modeling & ROI Projection

Financial projections assume a 5-year horizon with conservative market penetration rates and standard pharma margin structures. Sensitivity analysis accounts for raw material volatility and regulatory delays.

Break-Even Analysis: Month 18-20 depending on initial contract acquisition velocity. NPV at 8% discount rate: $89.3M. Payback period: 4.2 years.

6 Risk Assessment & Mitigation

Mitigation Strategies

• Dual-source critical APIs with qualified Asian and European suppliers
• Pre-submission meetings with FDA/EMA to align on CMC expectations
• Dynamic pricing algorithm integrated with commodity index tracking
• Redundant QC equipment and automated deviation tracking

7 Implementation Roadmap

8 Conclusion & Board Recommendation

The private-label pharmaceutical division presents a strategically sound, financially robust opportunity that aligns with Aevum Zenth's core competencies in integrated supply chain management, quality engineering, and B2B distribution. Regulatory hurdles are manageable given existing compliance infrastructure, and market timing favors early movers in cost-optimized generic and OTC segments.